Johnson & Johnson (JNJ) Assets Average (2009 - 2026)

Johnson & Johnson's (JNJ) quarterly Assets Average came in at $200.1 billion in Q1 2026, up 7.04% year-on-year from $186.9 billion in Q1 2025, and up 2.06% quarter-over-quarter from $196.0 billion in Q4 2025.

Johnson & Johnson (JNJ) Assets Average (2009 - 2026) Analysis & Trends

Johnson & Johnson has disclosed Assets Average across 18 years of filings, most recently posting $200.1 billion for Q1 2026.

  • Assets Average for Q1 2026 came in at $200.1 billion, up 7.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $200.1 billion (up 7.04% YoY), and the FY2025 annual result was $189.7 billion, up 9.1% from the prior year.
  • Assets Average came in at $200.1 billion for Q1 2026 at Johnson & Johnson, up from $196.0 billion in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $200.1 billion in Q1 2026 to a low of $166.8 billion in Q4 2023.
  • The 5-year median for Assets Average is $180.4 billion (2022), against an average of $183.5 billion.
  • Across the five-year window, Assets Average declined 11.43% in 2024 and gained 10.09% in 2025, its largest moves.
  • Johnson & Johnson's Assets Average stood at $176.4 billion in 2022, then fell by 5.45% to $166.8 billion in 2023, then grew by 7.43% to $179.2 billion in 2024, then rose by 9.39% to $196.0 billion in 2025, then rose by 2.06% to $200.1 billion in 2026.
  • The last three Assets Average figures came in at $200.1 billion (Q1 2026), $196.0 billion (Q4 2025), and $193.1 billion (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Assets Avg. (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn 83.03 Bn
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn 114.53 Bn
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn 200.05 Bn
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn 135.21 Bn
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn 132.78 Bn
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn 91.55 Bn
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn 57.65 Bn
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn 208.08 Bn
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn 88.26 Bn
10 Novartis Ag 108.28 Bn 107.60 Bn - -

Historic Data

Download Data
DateValue
Mar 29, 2026 200.05 Bn
Dec 28, 2025 196.01 Bn
Sep 28, 2025 193.10 Bn
Jun 29, 2025 193.53 Bn
Mar 30, 2025 186.89 Bn
Dec 29, 2024 179.20 Bn
Sep 29, 2024 179.69 Bn
Jun 30, 2024 176.53 Bn
Mar 31, 2024 169.76 Bn
Dec 31, 2023 166.81 Bn
Oct 1, 2023 178.87 Bn
Jul 2, 2023 193.83 Bn
Apr 2, 2023 191.67 Bn
Jan 1, 2023 181.25 Bn
Oct 2, 2022 176.42 Bn
Jul 3, 2022 178.04 Bn
Apr 3, 2022 180.19 Bn
Jan 2, 2022 180.62 Bn
Oct 3, 2021 177.83 Bn
Jul 4, 2021 174.50 Bn